CN116637115A - 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用 - Google Patents
川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用 Download PDFInfo
- Publication number
- CN116637115A CN116637115A CN202211673444.2A CN202211673444A CN116637115A CN 116637115 A CN116637115 A CN 116637115A CN 202211673444 A CN202211673444 A CN 202211673444A CN 116637115 A CN116637115 A CN 116637115A
- Authority
- CN
- China
- Prior art keywords
- ligustrazine
- application
- nitrone derivative
- preventing
- ligustrazine nitrone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FINHMKGKINIASC-UHFFFAOYSA-N tetramethyl-pyrazine Natural products CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 title claims abstract description 36
- -1 ligustrazine nitrone derivative Chemical class 0.000 title claims abstract description 20
- 208000002249 Diabetes Complications Diseases 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 9
- 239000003814 drug Substances 0.000 claims abstract description 18
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 8
- 239000002083 C09CA01 - Losartan Substances 0.000 claims abstract description 5
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960004773 losartan Drugs 0.000 claims abstract description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 42
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 18
- 208000017442 Retinal disease Diseases 0.000 claims description 11
- 206010038923 Retinopathy Diseases 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 208000010837 Diabetic eye disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 16
- 241000700159 Rattus Species 0.000 description 38
- 230000000694 effects Effects 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于药物技术领域，公开了一种川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用。本发明公开了川芎嗪硝酮衍生物与其他药物形成的组合物在制备用于预防和治疗糖尿病并发症药物中的应用，其他药物为losartan。
Description
本申请是申请日为2017年05月27日，申请号为201710392539.X，发明名称为“川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用”的中国发明专利申请的分案申请。
技术领域
本发明属于药物技术领域，具体涉及一种川芎嗪硝酮衍生物及其药物组合物在预防和治疗糖尿病并发症疾病中的应用。
背景技术
糖尿病是一种由于胰岛素分泌缺陷或胰岛素作用障碍所致的以高血糖为特征的代谢性疾病。持续高血糖与长期代谢紊乱等可导致全身组织器官，特别是眼、肾、心血管及神经系统的损害及其功能障碍和衰竭，严重者可引起失水，电解质紊乱和酸碱平衡失调等急性并发症酮症酸中毒和高渗昏迷。
糖尿病肾病(Diabetic Kidney Disease,DKD)是糖尿病最主要的微血管并发症之一，临床特征为蛋白尿，渐进性肾功能损害，高血压，水肿，晚期出现严重肾功能衰竭。DKD是目前引起终末期肾病的首要原因，约有30％～40％的糖尿病患者患有肾病。据IDF报道，2013年全球糖尿病患病率3.82亿人，25年内将增长到5.92亿人。
发明内容
本发明公开了一种川芎嗪硝酮衍生物及其药物组合物的新用途，即川芎嗪硝酮衍生物及其药物组合物在制备用于预防和治疗糖尿病并发症疾病的药物中的应用。所述衍生物具有如下通式(I)的结构：
其中，R1和R3各自独立的为C1-C6烷基；R2为C1-C6烷基或R4和R5各自独立的为仲丁基、异丁基、叔丁基、环戊基或环己基。
优选地，所述C1-C6烷基为甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基或正戊基。
进一步优选地，所述川芎嗪硝酮衍生物，具有下面的结构式：
本发明提供了所述川芎嗪硝酮衍生物及其药物组合物在预防和治疗糖尿病并发症疾病中的应用。
所述糖尿病并发症优选为糖尿病肾病和糖尿病性眼病。进一步优选的，所述糖尿病性眼病为视网膜病变、青光眼和白内障。
本发明还提供了所述川芎嗪硝酮衍生物及其药物组合物在制备药物中的应用，其中所述药物可用于预防和治疗糖尿病肾病及其并发症疾病。所述药物组合物包括治疗有效剂量的所述衍生物或其药学上可接受的盐，以及药学上可接受的载体。
包含所述川芎嗪硝酮衍生物的药物可以单独使用或者与其它药物组合使用，用来预防和治疗糖尿病并发症。可以联合使用的其它药物主要有临床常用口服抗糖尿病药，主要包括双胍类、磺脲类、葡萄糖苷酶抑制剂、噻唑烷二酮类、非磺脲类促胰岛素分泌药和二肽基肽酶抑制剂等；高血压药物，包括血管紧张素受体阻断剂(如losartan，氯沙坦)、血管紧张素转化酶抑制剂；和糖尿病肾病药物，包括叶酸。
本发明提供的川芎嗪衍生物TBN和TN-2可与临床上现有的糖尿病和糖尿病肾病治疗药物联合使用，通过协同作用提高疗效，降低现有临床药物的副作用，提高临床用药收益/风险比。
所述川芎嗪硝酮衍生物可与可用药物载体制成各种剂型，包括片剂、颗粒剂、针剂、粉剂、胶囊剂、悬浮剂。
优选地，所述川芎嗪硝酮衍生物的治疗有效剂量为0.001-2g/kg。
附图说明
图1为川芎嗪衍生物对STZ诱导DKD大鼠体重(图1a)、饮水量(图1b)和饮食量(图1c)的影响。###P<0.001,##P<0.01与对照组(Control)比较；***P<0.001,
*P<0.05与模型组(Model)比较。
图2为川芎嗪衍生物对STZ诱导DKD尿蛋白(图2a)和大鼠血糖(图2b)的影响。###P<0.001与对照组(Control)比较；***P<0.001,**P<0.05,*P<0.01与模型组(Model)比较。
图3为川芎嗪衍生物对STZ诱导DKD大鼠血清中肌酐(图3a)、尿素氮(图3b)、胆固醇(图3c)和甘油三酯(图3d)水平的影响。###P<0.001,##P<0.01与对照组(Control)比较；**P<0.05,*P<0.01与模型组(Model)比较。
图4为川芎嗪衍生物对STZ诱导DKD大鼠肾脏指数的影响。###P<0.001与对照组(Control)比较；**P<0.05,*P<0.01与模型组(Model)比较。
图5列出了糖尿病肾病模型大鼠视网膜病变出现的例数和出现时间。
具体实施方式
下面将结合本发明具体实施例对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例只是本发明一部分实施例，而不是全部的实施例。本领域技术人员应当理解，对本发明的具体实施例进行修改或者对部分技术特征进行同等替换，而不脱离本发明技术方案的精神，均应涵盖在本发明保护的范围中。
实施例1.STZ诱导糖尿病肾病大鼠模型的制作及分组
1.模型制作
选用SD大鼠(200±10g)作为造模动物，注射前禁食12h，注射时用柠檬酸缓冲液以1％的浓度溶解STZ，禁食大鼠称重后腹腔注射55mg/kg STZ放于笼内，确保大鼠24h充足饮水。STZ注射需要快速，在10min内注射完成。正常对照组注射等体积pH 4.5的柠檬酸-柠檬酸钠缓冲液。观察动物状态(出现多饮多尿)，STZ注射3周后尾静脉采血，测空腹血糖≥16.7mmol/L作为大鼠糖尿病肾病成模标准。
2.分组
DKD大鼠随机分配成6组，分别给予不同药物，给药6周后终止实验，观察药物对DKD大鼠的保护作用。
实施例2.川芎嗪衍生物对STZ诱导DKD大鼠体重、饮食和饮水的影响
每周观察大鼠造模后的一般情况和体重变化，一般情况包括大鼠的活动情况、精神状态、毛色、饮食、饮水量及尿量等。每周记录饮水量和饲料量。
川芎嗪衍生物对STZ诱导的糖尿病肾病大鼠的体重影响如图1a所示，TBN和TN-2对糖尿病肾病大鼠的体重基本没有影响；糖尿病肾病大鼠饮水量和饲料量变化分别如图1b和图1c所示，给予TBN和TN-2治疗组的DKD大鼠饮水量和饮食显著低于模型组，表明TBN和TN-2能够减缓DKD大鼠糖尿病疾病进程，从而改善DKD大鼠多饮多食的糖尿病症状。
实施例3.川芎嗪衍生物对STZ诱导的DKD大鼠视网膜病变的影响
实验过程中，每日给药时观察大鼠视网膜病变情况，记录不同组别大鼠发生视网膜病变的日期。
视网膜病变是糖尿病肾病的常见并发症之一，与糖尿病肾病的相关性较高。川芎嗪衍生物对STZ诱导的DKD大鼠视网膜病变的影响如(图5)所示，给予TBN和TN-2治疗后DKD大鼠出现视网膜病变的例数减少，出现视网膜病变的时间点相对延迟，研究结果表明川芎嗪衍生物TBN和TN-2能够减少并且延缓视网膜病变的发生。
实施例4.川芎嗪衍生物对STZ诱导DKD大鼠血糖和尿蛋白的影响
实验过程中，分别于造模完成后和给药完成后监测大鼠血糖，并收集一次24h尿液检测尿蛋白。
川芎嗪衍生物对STZ诱导的DKD大鼠血糖的影响如图2a所示，大鼠经STZ诱导3周后血糖显著升高，给予TBN和TN-2治疗6周后血糖显著下降。TBN和TN-2对STZ诱导的DKD大鼠尿蛋白的影响如图2b所示，给予TBN和TN-2治疗后的DKD大鼠尿液中的尿蛋白含量显著降低，且TBN与氯沙坦合用优于单独给予TBN治疗和单独给予氯沙坦治疗。
实施例5.川芎嗪衍生物对STZ诱导DKD大鼠血清生化指标的影响
给药6周后，大鼠麻醉后腹主动脉取血，静置1h后，3000rmp离心10min、-70℃保存。使用全自动生化分析仪检测血清中肌酐、尿素氮、胆固醇和甘油三酯的水平。
血清肌酐、尿素氮、胆固醇和甘油三酯水平能够反应机体脂质代谢、糖类代谢和肾脏功能等情况。川芎嗪衍生物对STZ诱导DKD大鼠血清中肌酐、尿素氮、胆固醇和甘油三酯的影响如图3所示，TBN和TN-2能够显著降低血清中的肌酐(图3a)、尿素氮(图3b)、胆固醇(图3c)和甘油三酯(图3d)的水平，且呈剂量依赖性，显示出对STZ诱导糖尿病肾病大鼠脂质代谢、糖类代谢和肾脏功能的改善作用。
实施例6.川芎嗪衍生物对STZ诱导DKD大鼠肾脏指数的影响
给药6周后，用高压灭菌手术器械开腹腔统一分离肾脏组织，生理盐水清洗，滤纸吸干后精细天平称重，然后置于-80℃冰箱保存备用。肾脏指数(相对肾重)即肾重(mg)/体重(g)＝BW/KW。
肾脏指数能够在一定程度上反应糖尿病肾病的病理情况。川芎嗪衍生物对STZ诱导的DKD大鼠肾脏指数的影响如图4所示，TBN和TN-2能够显著降低DKD大鼠的肾脏指数，表明TBN和TN-2能够延缓糖尿病肾病的疾病进程。
Claims (6)
1.川芎嗪硝酮衍生物所形成的组合物在制备预防和治疗糖尿病并发症疾病的药物中的应用，所述川芎嗪硝酮衍生物所形成的组合物包含川芎嗪硝酮衍生物和losartan；所述川芎嗪硝酮衍生物具有如下结构式：
2.根据权利要求1所述的应用，其中所述糖尿病并发症疾病为糖尿病肾病和糖尿病性眼病。
3.根据权利要求2所述的应用，其中所述糖尿病性眼病为视网膜病变、青光眼和白内障。
4.根据权利要求1-3任一项所述的应用，其中所述组合物包括治疗有效剂量的所述川芎嗪硝酮衍生物或其药学上可接受的盐，以及药学上可接受的载体。
5.根据权利要求4所述的应用，其中所述组合物的剂型为片剂、颗粒剂、针剂、粉剂、胶囊剂或悬浮剂。
6.根据权利要求1-3任一项所述的应用，其中川芎嗪硝酮衍生物的治疗有效剂量为0.001～2g/kg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211673444.2A CN116637115A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710392539.XA CN107157999A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN202211673444.2A CN116637115A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710392539.XA Division CN107157999A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116637115A true CN116637115A (zh) | 2023-08-25 |
Family
ID=59821915
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211727058.7A Pending CN115887460A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN201710392539.XA Pending CN107157999A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN202211673444.2A Pending CN116637115A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211727058.7A Pending CN115887460A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN201710392539.XA Pending CN107157999A (zh) | 2017-05-27 | 2017-05-27 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11197855B2 (zh) |
| EP (1) | EP3632440A4 (zh) |
| JP (1) | JP6954698B2 (zh) |
| CN (3) | CN115887460A (zh) |
| AU (1) | AU2018276686B2 (zh) |
| CA (1) | CA3064976C (zh) |
| WO (1) | WO2018218961A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887460A (zh) * | 2017-05-27 | 2023-04-04 | 青岛海蓝医药有限公司 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
| CN116003334A (zh) * | 2019-04-01 | 2023-04-25 | 广州喜鹊医药有限公司 | 硝酮嗪晶型、制备方法及应用 |
| CN114344304B (zh) * | 2020-10-14 | 2023-06-30 | 广州喜鹊医药有限公司 | 川芎嗪硝酮化合物在制备预防和/或治疗肾性贫血药物中的应用 |
| US20220202812A1 (en) * | 2019-11-22 | 2022-06-30 | Qingdao Hailan Pharmaceuticals Co., Ltd. | Use of ligustrazine nitrone derivatives in treatment and prevention of diabetic complication diseases |
| CN116650411A (zh) * | 2022-02-25 | 2023-08-29 | 广州喜鹊医药有限公司 | 一种注射用硝酮嗪药物组合物及其制备方法 |
| WO2023165479A1 (zh) * | 2022-03-02 | 2023-09-07 | 广州喜鹊医药有限公司 | 硝酮化合物或其在药学上可接受的盐与sglt-2抑制剂联合应用 |
| CN116850188A (zh) * | 2023-05-29 | 2023-10-10 | 广州喜鹊医药有限公司 | 川芎嗪硝酮衍生物在制备预防或治疗2型糖尿病药物中的应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997002032A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
| US20070203211A1 (en) * | 2003-04-15 | 2007-08-30 | Sankyo Company, Limited | Drug for preventing or treating angiogenic eye diseases |
| CN101468970A (zh) * | 2008-04-25 | 2009-07-01 | 暨南大学 | 一种硝酮类化合物及其制备方法和在制药中的应用 |
| CN102292084A (zh) * | 2009-01-23 | 2011-12-21 | 韩美控股株式会社 | 包含氨氯地平和氯沙坦的固体药物组合物 |
| CN102311396A (zh) * | 2010-07-05 | 2012-01-11 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| CN105963298A (zh) * | 2016-05-06 | 2016-09-28 | 广州喜鹊医药有限公司 | 川芎嗪衍生物硝酮嗪在预防和治疗脑损伤疾病中的应用 |
| US20200179369A1 (en) * | 2015-07-29 | 2020-06-11 | Takeda Gmbh | Treatment of diabetic nephropathy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101816655A (zh) * | 2009-12-16 | 2010-09-01 | 成都百康医药工业药理毒理研究院 | 包含瑞格列奈和川芎嗪药物制剂及在糖尿病并发症中用途 |
| CN102552267A (zh) * | 2012-02-17 | 2012-07-11 | 上海市中医医院 | 川芎嗪在制备治疗造影剂肾病药物中的应用 |
| CN105017165B (zh) * | 2015-07-07 | 2018-04-03 | 广州喜鹊医药有限公司 | 一种新的吡嗪衍生物及其制备方法和医药应用 |
| CN115887460A (zh) * | 2017-05-27 | 2023-04-04 | 青岛海蓝医药有限公司 | 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用 |
-
2017
- 2017-05-27 CN CN202211727058.7A patent/CN115887460A/zh active Pending
- 2017-05-27 CN CN201710392539.XA patent/CN107157999A/zh active Pending
- 2017-05-27 CN CN202211673444.2A patent/CN116637115A/zh active Pending
-
2018
- 2018-05-25 WO PCT/CN2018/000194 patent/WO2018218961A1/zh active Application Filing
- 2018-05-25 JP JP2020515801A patent/JP6954698B2/ja active Active
- 2018-05-25 AU AU2018276686A patent/AU2018276686B2/en active Active
- 2018-05-25 US US16/602,714 patent/US11197855B2/en active Active
- 2018-05-25 EP EP18809367.8A patent/EP3632440A4/en active Pending
- 2018-05-25 CA CA3064976A patent/CA3064976C/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997002032A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
| US20070203211A1 (en) * | 2003-04-15 | 2007-08-30 | Sankyo Company, Limited | Drug for preventing or treating angiogenic eye diseases |
| CN101468970A (zh) * | 2008-04-25 | 2009-07-01 | 暨南大学 | 一种硝酮类化合物及其制备方法和在制药中的应用 |
| CN102292084A (zh) * | 2009-01-23 | 2011-12-21 | 韩美控股株式会社 | 包含氨氯地平和氯沙坦的固体药物组合物 |
| CN102311396A (zh) * | 2010-07-05 | 2012-01-11 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
| US20200179369A1 (en) * | 2015-07-29 | 2020-06-11 | Takeda Gmbh | Treatment of diabetic nephropathy |
| CN105963298A (zh) * | 2016-05-06 | 2016-09-28 | 广州喜鹊医药有限公司 | 川芎嗪衍生物硝酮嗪在预防和治疗脑损伤疾病中的应用 |
Non-Patent Citations (3)
| Title |
|---|
| 周艳: "川芎嗪对高脂高糖饮食与STZ诱致大鼠肾损伤保护作用的抗氧化机制", 中国实验方剂学杂志, vol. 17, no. 23, 5 December 2011 (2011-12-05), pages 200 * |
| 王全顺;刘辉;张佳楠;苏宁;任建民;: "转化生长因子β1在糖尿病肾病大鼠肾组织中的表达及川芎嗪与氯沙坦联合干预对其影响的研究", 中华临床医师杂志(电子版), no. 17, 1 September 2011 (2011-09-01) * |
| 邢玉微: "复方血栓通胶囊对糖尿病大鼠微血管保护作用及机制探讨", 中国硕士学位论文全文数据库（硕士） 医药卫生科技辑, 15 December 2010 (2010-12-15), pages 1 - 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020521002A (ja) | 2020-07-16 |
| WO2018218961A1 (zh) | 2018-12-06 |
| EP3632440A1 (en) | 2020-04-08 |
| JP6954698B2 (ja) | 2021-10-27 |
| CN115887460A (zh) | 2023-04-04 |
| CA3064976C (en) | 2022-06-28 |
| CA3064976A1 (en) | 2018-12-06 |
| US20200155548A1 (en) | 2020-05-21 |
| AU2018276686B2 (en) | 2021-01-21 |
| EP3632440A4 (en) | 2021-02-17 |
| US11197855B2 (en) | 2021-12-14 |
| CN107157999A (zh) | 2017-09-15 |
| AU2018276686A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116637115A (zh) | 川芎嗪硝酮衍生物组合物在预防和治疗糖尿病并发症疾病中的应用 | |
| EP2135603B1 (en) | Compositions and methods for increasing insulin sensitivity | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| US8492426B1 (en) | Use of carvedilol for treatment of diabetes mellitus | |
| US20130172414A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| US20220202812A1 (en) | Use of ligustrazine nitrone derivatives in treatment and prevention of diabetic complication diseases | |
| JP2014527506A (ja) | 糖尿病治療のための組み合わせ | |
| WO2024109153A1 (zh) | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 | |
| CN102727894B (zh) | 一种治疗糖尿病及其并发症的药物组合物及其应用 | |
| CN112316150A (zh) | 一种用于预防或治疗代谢或损伤相关疾病的药物组合物 | |
| RU2653478C2 (ru) | Способ улучшения функции печени | |
| JP6657101B2 (ja) | 糖尿病及びそれから生じる疾患合併症の治療のための化合物 | |
| CN103230594A (zh) | α-葡萄糖苷酶抑制剂和B族维生素的药物组合物 | |
| CN113599385A (zh) | 阿夫唑嗪在制备治疗糖尿病及其并发症药物中的应用 | |
| CN112999216B (zh) | 一种含有泰格列净的用于治疗糖尿病心肌病的药物组合物 | |
| WO2023165479A1 (zh) | 硝酮化合物或其在药学上可接受的盐与sglt-2抑制剂联合应用 | |
| CN115429788B (zh) | 一种治疗脱髓鞘疾病的药物及应用 | |
| US11318153B2 (en) | Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function | |
| CN113509544B (zh) | 一种具有降血糖作用的药物组合物 | |
| CN101111266A (zh) | 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物 | |
| CN103599540A (zh) | 含有格列奈类药物和b族维生素的药物组合物及其用途 | |
| CN116919943A (zh) | 葛根素晶v型物质用于预防治疗糖尿病心肌病的用途 | |
| CN104125958B (zh) | 从茑萝属分离的化合物以及作为有效成分包含该化合物的用于预防或治疗糖尿病的组合物 | |
| CN117462627A (zh) | 靶向肠道菌群-ucp1轴的组合物制备方法及用途 | |
| WO2021127359A1 (en) | Use of lemborexant for treating insomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |